Product Information
CEVIMELINE HCL 30 MG CAPSULE is a generic product labeled by Sun Pharmaceutical Industries Inc., priced at $0.7289 per EA under NDC 63304047901. Its NADAC has been published 658 times since Nov 28, 2013.
FDA first approved this application on Jan 11, 2000. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Sun Pharmaceutical Industries Inc.NDC
63304047901
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CEVIMELINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA020989FDA Approved
1/11/2000
TE Code
AB
On Market Since
3/10/2016
Pharmacological Classes
Price Statistics
The NADAC for CEVIMELINE HCL 30 MG CAPSULE has been published 658 times since Nov 28, 2013, and over the history we have for it it has declined 66.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7289 per EA |
|---|---|
| All-time high | $2.2833 (Jan 15, 2014) |
| All-time low | $0.6268 (Nov 20, 2024) |
| 52-week high | $0.7289 |
| 52-week low | $0.6572 |
| Median price | $1.1463 |
| Average price | $1.2814 |
| Largest weekly change | +42.0% (Aug 17, 2022) |
| Weeks tracked | 658 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Cevimeline market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sun Pharmaceutical Industries Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cevimeline market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CEVIMELINE HCL 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CEVIMELINE HCL 30 MG CAPSULE, manufactured by Sun Pharmaceutical Industries Inc., is $0.7289 per EA (NDC 63304047901), effective Sep 30, 2026.
How has the price of CEVIMELINE HCL 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CEVIMELINE HCL 30 MG CAPSULE has declined 66.2%. It has been tracked across 658 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CEVIMELINE HCL 30 MG CAPSULE?
Since Nov 28, 2013, the NADAC for CEVIMELINE HCL 30 MG CAPSULE has ranged from a low of $0.6268 (Nov 20, 2024) to a high of $2.2833 (Jan 15, 2014), with a median of $1.1463 per EA.
Are there cheaper alternatives to CEVIMELINE HCL 30 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of CEVIMELINE HCL 30 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CEVIMELINE HCL 30 MG CAPSULE?
CEVIMELINE HCL 30 MG CAPSULE (NDC 63304047901) is labeled by Sun Pharmaceutical Industries Inc., and CMS classifies it as a generic product.